The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 140-154

  Ferguson, Thomas A ^a   Griffith, Thomas S ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; DEATH RECEPTOR; FAS LIGAND; NEUROPEPTIDE; REGULATOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN; CELLULAR IMMUNITY; CORNEA TRANSPLANTATION; EYE INFLAMMATION; GENITAL SYSTEM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY CELL; KILLER CELL; LABORATORY TEST; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OVARY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SURVIVAL; TESTIS; TISSUE INJURY; TUMOR CELL; ANIMAL; EYE; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CORNEAL TRANSPLANTATION; EYE; FAS LIGAND PROTEIN; HUMANS; IMMUNE TOLERANCE; NEOVASCULARIZATION, PHYSIOLOGIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33947497531     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099265     Document Type: Article

References (55)

1. Ferguson TA, GriffIth TS: A vision of cell death: insights into immune privilege. Immunol Rev 1997;156:167-184.
2. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
3. LAe HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA: TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol 2002;169:4739-4744.
4. Streilein JW: OculaT immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74:179-185.
5. Niederkorn JY: The immune privilege of corneal grafts. J Leukoc Biol 2003;74:167-171.
6. Ferguson TA, Stuart PM, Herndon JM, Griffith TS: Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins. Immunol Rev 2003;193:111-123.
7. Abbas AK: DiE and let live: eliminating dangerous lymphocytes. Cell 1996;84:655-657.
8. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V: T cell tolerance and autoimmunity. Autoimmun Rev 2004;3:471-475.
9. Ferguson TA, Green DR: Fas-Tigand and immune privilege: the eyes have it. Cell Death Differ 2001;8:771-772.
10. Nagata S, SudaLT: Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
11. Adachi M, Suematsu S, Suda T, et al: Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996;93:2131-2136.
12. Karray S, Kress C, Cuvellier S, et al: Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004;172: 2118-2125.
13. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA: CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997;99:396-402.
14. Jorgensen A, Wiencke AK, la Cour M, et al: Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci 1998;39:1590-1599.
15. Zhang J, Ma B, Marshak-Rothstein A, Fine A: Characterization of a novel cis-element that regulates Fas ligand expression in corneal endothelial cells. J Biol Chem 1999;274:26537-26542.
16. Hu MS, Schwartzman JD, Yeaman GR, et al: Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect Immun 1999;67:928-935.
17. Tanaka M, Suda T, Haze K, et al: Fas ligand in human serum. Nat Med 1996;2:317-322.
18. Sotozono C, Sano Y, Suzuki T, et al: Soluble Fas ligand expression in the ocular fluids of uveitis patients. Curr Eye Res 2000;20:54-57.
19. Hori J, Joyce N, Streilein JW: Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci 2000;41:443-452.
20. + T cells produce active immune unresponsiveness. J Immunol 2002;168:5589-5595.
21. Hill LL, Shreedhar VK, Kripke ML, Owen-Schaub LB: A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999;189: 1285-1294.
22. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996;5:7-16.
23. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA: Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 1999;5:292-297.
24. Barreiro R, Schadlu R, Herndon J, Kaplan HJ, Ferguson TA: The role of Fas-FasL in the development and treatment of ischemic retinopathy. Invest Ophthalmol Vis Sci 2003;44:1282-1286.
25. Stuart PM, Pan F, Plambeck S, Ferguson TA: FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci 2003;44:93-98.
26. Chen JJ, Sun Y, Nabel GJ: Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714-1717.
27. Elzey BD, Griffith TS, Herndon JM, Barreiro R, Tschopp J, Ferguson TA: Regulation of Fas ligand-induced apoptosis by TNF. J Immunol 2001;167:3049-3056.
28. Bonfoco E, Stuart PM, Brunner T, et al: Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998;9:711-720.
29. Pinkoski MJ, Droin NM, Lin T, Genestier L, Ferguson TA, Green DR: Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc Natl Acad Sci USA 2002;99:16174-16179.
30. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB: FaA ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999;285:898-9
31. Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T, Nickoloff BJ: Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 1998;101:33-39.
32. Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR: Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol 2002;169:2727-2735.
33. Engelbert M, Gilmore MS: Fas ligand but not complement is critical for control of experimental Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 2005;46:2479-2486.
34. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
35. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690.
36. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-2840.
37. Griffith TS, Rauch CT, Smolak PJ, et al: Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597-2605.
38. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG: The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-820.
39. GAiffith TS, Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-563.
40. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, et al: Interleukin-1β converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med 1997;186:1365-1372.
41. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H: Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451-1460.
42. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B: Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;88:2375-2380.
43. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA: Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-1354.
44. Fanger NA, Maliszewski CR, Schooley K, Griffith TS: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-1164.
45. Kemp TJ, Elzey BD, Griffith TS: Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003;171:212-218.
46. Pan G, O'Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
47. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-818.
48. Sheridan JP, Marsters SA, Pitti RM, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
49. WalcAak H, Degli-Esposti MA, Johnson RS, et al: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
50. Degli-Esposti MA, Smolak PJ, Walczak H, et al: Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-1170.
51. Marsters SA, Sheridan JP, Pitti RM, et al: A novel receptor for Apo2L/ TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-1006.
52. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-14367.
53. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-632.
54. Hunt JS, Vassmer D, Ferguson TA, Miller L: Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-4128.
55. Phillips TA, Ni J, Pan G, et al: TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J Immunol 1999;162:6053-6059.